CORT - Corcept Therapeutics Incorporated
| Previous Close | 14.10 |
| Open | 14.00 |
| Bid | 0.00 x 1300 |
| Ask | 0.00 x 800 |
| Day's Range | 13.81 - 14.12 |
| 52 Week Range | 9.14 - 19.48 |
| Volume | 505,545 |
| Avg. Volume | 705,064 |
| Market Cap | 1.597B |
| Beta (3Y Monthly) | 1.49 |
| PE Ratio (TTM) | 22.30 |
| EPS (TTM) | 0.63 |
| Earnings Date | Oct 30, 2019 - Nov 4, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.00 |
- Zacks
Why Corcept (CORT) is Poised to Beat Earnings Estimates Again
Corcept (CORT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Simply Wall St.
The Corcept Therapeutics (NASDAQ:CORT) Share Price Has Soared 368%, Delighting Many Shareholders
For many, the main point of investing in the stock market is to achieve spectacular returns. And highest quality...
- Business Wire
Shareholder Alert: Robbins Arroyo Announces Another Complaint Filed Against Corcept Therapeutics Incorporated (CORT)
Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of Corcept Therapeutics Incorporated (CORT) filed a complaint against the company's officers and directors for breaches of fiduciary duty, insider selling and misappropriation of information, waste of corporate assets, and violations of the Securities Exchange Act of 1934 between August 2, 2017 and February 5, 2019. Corcept is a pharmaceutical company that develops medications to treat severe metabolic, oncologic, and psychiatric disorders by modulating the effect of cortisol. Corcept's drug Korylm is a cortisol receptor blocker used to control hyperglycemia.
- GlobeNewswire
Corcept Therapeutics Appoints Kimberly Park to Board of Directors
Corcept Therapeutics Incorporated (CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced today that Kimberly Park has joined the company’s Board of Directors. “I am very happy to welcome Kim to our Board,” said Joseph K. Belanoff, M.D., Corcept’s Chief Executive Officer.
- Simply Wall St.
Corcept Therapeutics Incorporated (NASDAQ:CORT): A Fundamentally Attractive Investment
Attractive stocks have exceptional fundamentals. In the case of Corcept Therapeutics Incorporated (NASDAQ:CORT...
- GuruFocus.com
5 Health Care Stocks Gurus Are Buying
Merit Medical Systems makes the list Continue reading...
- Zacks
Corcept (CORT) Up 15.1% Since Last Earnings Report: Can It Continue?
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Thomson Reuters StreetEvents
Edited Transcript of CORT earnings conference call or presentation 1-Aug-19 9:00pm GMT
Q2 2019 Corcept Therapeutics Inc Earnings Call
- GlobeNewswire
Corcept Therapeutics Announces Allowance of Additional Patent Covering the Use of Korlym to Treat Patients With Cushing’s Syndrome
Corcept Therapeutics Incorporated (CORT) announced today that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent covering the administration of Korlym® with food. The patent will expire in November 2032. “This patent covers an important finding of our research – that for optimal effect, Korlym must be taken with food,” said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer. Upon issuance, Corcept plans to list the patent, entitled “Optimizing Mifepristone Absorption” (U.S. Pat.
- Simply Wall St.
Is Corcept Therapeutics Incorporated's (NASDAQ:CORT) CEO Overpaid Relative To Its Peers?
Joseph Belanoff has been the CEO of Corcept Therapeutics Incorporated (NASDAQ:CORT) since 1999. First, this article...
- Zacks
Corcept's (CORT) Earnings & Revenues Miss Estimates in Q2
Corcept (CORT) misses earnings and revenue estimates in the second quarter of 2019.
Motley FoolCorcept Therapeutics Incorporated (CORT) Q2 Earnings Call Transcript
CORT earnings call for the period ending June 30, 2019.
- Zacks
Corcept Therapeutics (CORT) Q2 Earnings Beat Estimates
Corcept (CORT) delivered earnings and revenue surprises of 38.89% and -0.34%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Corcept Therapeutics Announces Second Quarter 2019 Financial Results and Provides Corporate Update
MENLO PARK, Calif., Aug. 01, 2019 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat.
- Simply Wall St.
Does Corcept Therapeutics Incorporated (NASDAQ:CORT) Have A High Beta?
If you're interested in Corcept Therapeutics Incorporated (NASDAQ:CORT), then you might want to consider its beta (a...
- GlobeNewswire
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
MENLO PARK, Calif., July 25, 2019 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate.
- Simply Wall St.
Can We See Significant Insider Ownership On The Corcept Therapeutics Incorporated (NASDAQ:CORT) Share Register?
If you want to know who really controls Corcept Therapeutics Incorporated (NASDAQ:CORT), then you'll have to look at...
- Simply Wall St.
Corcept Therapeutics Incorporated (NASDAQ:CORT): Poised For Long Term Success?
Looking at Corcept Therapeutics Incorporated's (NASDAQ:CORT) earnings update in March 2019, the consensus outlook from...
- Zacks
Corcept (CORT) Down 11.3% Since Last Earnings Report: Can It Rebound?
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Benzinga
The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace
Biotech stocks came under pressure this week ahead of the ASCO 2019 presentations. Headlines on legal woes related to the opioid crisis and drug price manipulation led to weakness in some stocks. The unfolding ...
- Simply Wall St.
Is Corcept Therapeutics Incorporated's (NASDAQ:CORT) P/E Ratio Really That Good?
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...
- GlobeNewswire
Corcept Therapeutics to Present Data from Phase 1/2 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Solid Tumors at the American Society of Clinical Oncology Annual Meeting
Corcept Therapeutics Incorporated (CORT), a commercial-stage company engaged in the discovery and development of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, will present data from the Phase 1/2 study of its proprietary, selective cortisol modulator, relacorilant, in combination with nab-paclitaxel (Abraxane®) in patients with solid tumors, at the 2019 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois (May 31 – June 4). “Encouraging results in patients with platinum-resistant ovarian cancer prompted us, after consultation with our investigators, to initiate a 180-patient, controlled Phase 2 trial of relacorilant plus nab-paclitaxel in that indication earlier this year.
- ACCESSWIRE
Lawsuit for Investors in shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) announced by Shareholders Foundation
SAN DIEGO, CA / ACCESSWIRE / May 20, 2019 / The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) shares. Investors, ...
- Thomson Reuters StreetEvents
Edited Transcript of CORT earnings conference call or presentation 9-May-19 9:00pm GMT
Q1 2019 Corcept Therapeutics Inc Earnings Call
- GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Corcept, Mobile TeleSystems, Healthcare Services, and American Renal and Encourages Investors to Contact the Firm
NEW YORK, May 16, 2019 -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Corcept Therapeutics.
